King Pharmaceuticals KG Diversified Legacy Reinsurance — Total AmTrust Reinsurance PPD

Similar metrics at other companies

CBGlobal Reinsurance Non Casualty — Short-Duration PPD

-$5.25M+25.0%

CBGlobal Reinsurance Casualty — Short-Duration PPD

-$2.25M-213%

CBSegment Global Reinsurance — Other PPD adjustments

$0+100%

CBNorth America Non Casualty — Short-Duration PPD

-$95.5M+15.5%

CBNorth America Other Casualty — Short-Duration PPD

$40.5M+57.3%

CBNorth America General Liability — Short-Duration PPD

$79.75M-23.1%

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-67.6%

Enterprise value$184.93M-50.0%

P/E1.2×—

P/S1.6×-24.3×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept kg:LiabilityforUnpaidClaimsandClaimsAdjustmentExpensePeriodIncreaseDecreaseNetofCommissionChanges.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's diversified legacy reinsurance — total amtrust reinsurance ppd.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's diversified legacy reinsurance — total amtrust reinsurance PPD?: King Pharmaceuticals (KG) reported diversified legacy reinsurance — total amtrust reinsurance PPD of $274K in Q1 2026.
What does diversified legacy reinsurance — total amtrust reinsurance PPD mean?: This metric tracks the total Prior Period Development (PPD) specifically related to the AmTrust reinsurance portfolio within the legacy segment. It captures the impact of re-estimating ultimate losses for claims incurred in previous periods, which directly affects the segment's profitability. Positive or negative development provides insight into the accuracy of initial loss reserves and the overall stability of the legacy book.